ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

RGC vs CRON // RSI-14 & 200D SMA MOMENTUM

Regencell Bioscience Holdings Limited (NASDAQ) VS. Cronos Group Inc. Common Share (NASDAQ) • 15-METRIC TALLY: RGC 1 — CRON 3
▲ RSI-14 & 200D SMA MOMENTUM LEADER: CRON
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RGC VS. CRON) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC RGC CRON SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 42.80% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) — -4.50% — TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -0.10% 0.01% -0.11 CRON /fcf-yield <GO>
Operating Margin — -11.90% — TIE /operating-margins <GO>
Net Profit Margin — -2.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 24.60% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 15.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 6/9 -4.00 CRON /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 44.1 55.0 -10.90 CRON /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $3.40B $1.24B $2.16B RGC /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR RGC REV CRON REV RGC GROSS % CRON GROSS % RGC FCF CRON FCF
FY 2025 $0 $146.6M — 42.8% -$3.3M $149.0K
FY 2024 $0 $117.6M — 21.4% -$4.0M $6.4M
FY 2023 $0 $87.2M — — -$5.0M -$42.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RGC // BETA —
CRON // BETA —